|
 |
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print June 16, 2003
J. Lipid Res., doi:10.1194/jlr.M300059-JLR200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Molecular Medicine, National Public Health Institute, Helsinki FIN-00251
Corresponding Author: sarah.siggins{at}ktl.fi
Plasma phospholipid transfer protein (PLTP) is an important regulator of plasma high density lipoprotein (HDL) levels and HDL particle distribution. The protein is present in the circulation in two forms, one with high and the other with low phospholipid transfer activity. We have used the human hepatoma cell line, HepG2, as a model to study the PLTP secreted from hepatic cells. PLTP activity was secreted by the cells into serum-free culture medium as a function of time. However, modification of a previously established ELISA mass assay to include a denaturing sample pre-treatment with the anionic detergent sodium dodecyl sulphate (SDS) was required for the detection of the secreted PLTP protein. The HepG2 PLTP could be enriched by Heparin-Sepharose affinity chromatography and eluted in size-exclusion chromatography at a position corresponding to the size of 160 kDa. PLTP co-eluted with apoE but not with apoB-100 or apoA-I. A portion of PLTP was retained by an anti-apoE immunoaffinity column together with apoE, suggesting an interaction between these two proteins. Furthermore, antibodies against apoE but not those against apoB-100 or apoA-I were capable of inhibiting PLTP activity. These results show that the HepG2-derived PLTP resembles in several aspects the high-activity form of PLTP found in human plasma. The findings support a model in which PLTP is secreted by the liver as an active form that is, during lipid transfer processes between lipolysed chylomicrons/VLDL and HDL, converted into the low-activity complex.
Revised on May 16, 2003
Accepted on June 5, 2003
Phospholipid transfer protein (PLTP) secreted by HepG2 cells resembles the high-activity PLTP form in human plasma
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Bancells, S. Benitez, M. Jauhiainen, J. Ordonez-Llanos, P. T. Kovanen, S. Villegas, J. L. Sanchez-Quesada, and K. Oorni High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level J. Lipid Res., March 1, 2009; 50(3): 446 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakanishi, R. Vikstedt, S. Soderlund, M. Lee-Rueckert, A. Hiukka, C. Ehnholm, M. Muilu, J. Metso, J. Naukkarinen, L. Palotie, et al. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity J. Lipid Res., February 1, 2009; 50(2): 183 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Christoffersen, M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, M. Boesl, B. Dahlback, and L. B. Nielsen Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice J. Biol. Chem., January 25, 2008; 283(4): 1839 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Cheung and J. J. Albers Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins J. Lipid Res., June 1, 2006; 47(6): 1315 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |